nach oben

Reactions Weekly

Erschienen in:

01.08.2019 | Case report

Bortezomib/melphalan/prednisolone

Diarrhoea, mucositis and disorientation: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective study involving 59 patients who had been treated with bortezomib, melphalan and prednisolone from January 2012 to April 2017, three patients [ages and sexes not stated] were described, of whom, a patient developed diarrhoea, another patient developed mucositis, and the remaining patient developed disorientation following treatment with bortezomib, melphalan and prednisolone (VMP regimen) for multiple myeloma. …

Cho SH, et al. Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment. Turkish Journal of Hematology 36: 106-111, No. 2, 3 May 2019. Available from: URL: http://doi.org/10.4274/tjh.galenos.2019.2019.0306 - SouthKorea

Titel: Bortezomib/melphalan/prednisolone
Diarrhoea, mucositis and disorientation: 3 case reports
Publikationsdatum: 01.08.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-65839-8

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Bortezomib/melphalan/prednisolone

Diarrhoea, mucositis and disorientation: 3 case reports

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Bevacizumab

Methotrexate

Immunosuppressants

Pembrolizumab

Filgrastim

Alteplase/dabigatran-etexilate/idarucizumab